Our Science

Pioneering a new wave in cancer therapy that stops immune evasion where it starts: in the tumor.

A tumor often creates barriers or bottlenecks not to proliferate but to evade immune detection and control.

At Larkspur, we couple insights into the chemistry of the tumor with LarkX, our proprietary machine-learning-enabled gene signature platform, to unlock previously intractable targets shared by both the tumor and the immune system.

LarkX, our proprietary machine-learning-enabled gene signature platform, identifies pathways with cancer cell-intrinsic adaptations that drive immune evasion.

LarkX bioinformatics approach focuses treatment on likely responders resulting in smaller, more targeted trials that drive rapid proof of concept and enable expansion into indications enriched for responders.

Our first-in-class pipeline programs are initially focused on colorectal cancer (CRC), with opportunities to expand to multiple cancers.

Target Validation
Lead Discovery
Lead Optimization

Program 1

A novel approach to improve antigen-presenting function through lipid remodeling

Program 2

Novel therapy targeting Pin1 to program fibroblasts to drive a pro-immune phenotype in the tumor microenvironment

Program 3

A biologic targeting key B cell checkpoint TIM-1